Skip to main content
SpringerLink
Log in

Afatinib/gefitinib

Development of resistance to Tyrosine kinase inhibitor therapy during treatment of lung adenocarcinoma: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Shee-Chai C, et al. Small Cell Transformation and T790M Mutation as Coresistance Mechanisms for First-line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy Failure. Journal of Thoracic Oncology 12: e171-e173, No. 10, Oct 2017. Available from: URL: http://doi.org/10.1016/j.jtho.2017.06.068 - Malaysia

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Afatinib/gefitinib. Reactions Weekly 1679, 16 (2017). https://doi.org/10.1007/s40278-017-38741-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-017-38741-9

Search

Navigation